Wall Street Zen lowered shares of Organogenesis (NASDAQ:ORGO – Free Report) from a sell rating to a strong sell rating in a research note published on Sunday,Wall Street Zen reports.
Other equities research analysts also recently issued research reports about the company. Weiss Ratings raised Organogenesis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, November 9th. Truist Financial reduced their price objective on Organogenesis from $3.00 to $2.00 and set a “hold” rating on the stock in a research note on Friday, August 7th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average target price of $4.33.
View Our Latest Analysis on ORGO
Organogenesis Price Performance
Shares of ORGO opened at $0.81 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.76 and a current ratio of 3.32. The stock has a 50 day simple moving average of $1.19 and a 200 day simple moving average of $2.23. Organogenesis has a 52-week low of $0.73 and a 52-week high of $6.32. The firm has a market capitalization of $105.15 million, a PE ratio of -0.66 and a beta of 1.48.
Organogenesis (NASDAQ:ORGO – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The company had revenue of $45.46 million for the quarter, compared to analyst estimates of $52.10 million. Organogenesis had a negative return on equity of 55.28% and a negative net margin of 39.34%.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the stock. Waverly Advisors LLC purchased a new position in Organogenesis in the 2nd quarter worth approximately $25,000. Sequoia Financial Advisors LLC bought a new stake in shares of Organogenesis during the 2nd quarter worth $33,000. Pallas Capital Advisors LLC purchased a new position in Organogenesis in the second quarter worth $37,000. The Manufacturers Life Insurance Company purchased a new position in Organogenesis in the second quarter worth $44,000. Finally, Capital Square LLC purchased a new position in Organogenesis in the second quarter worth $45,000. Institutional investors own 49.57% of the company’s stock.
About Organogenesis
Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures and commercializes products for advanced wound care and surgical and sports medicine. The company’s products are designed to support tissue repair and healing in a range of clinical settings. Its portfolio includes wound-care products such as Apligraf, a bioengineered skin substitute, and products made from or incorporating materials including placental tissue and purified collagen. Organogenesis also offers products for surgical and sports medicine applications.
Featured Articles
- Five stocks we like better than Organogenesis
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.
